Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK p.Gly1202Arg (p.G1202R) ALK p.Gly1202Arg (p.G1202R)
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- The G1202R ALK mutation was found in a crizotinib-resistant ALK-rearranged NSCLC, and the mutant ALK fusion was further characterized in Ba/F3 cells. EML4-ALK variant 1 with G1202R mutation was expressed in Ba/F3 and subject to 17-AAG. IC50 for cell number in response to 17-AAG was 33.4 nM, in contrast to IC50 for EML4-ALK wild-type, which was 98.9 nM, suggesting sensitization of this variant to HSP90 inhibition.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1352
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/171
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Tanespimycin
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 22277784
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Tanespimycin | Sensitivity | true |